A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
NCT ID: NCT00108095
Last Updated: 2017-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
701 participants
INTERVENTIONAL
2004-10-31
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
NCT00600990
Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
NCT03297021
A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
NCT00231777
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
NCT00090246
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
NCT00090155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravenous ondansetron
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Laparoscopic/laparotomic gynecological procedure of laparoscopic gallbladder removal
Exclusion Criteria
* Post-menopausal
* Not undergoing general anesthesia
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Montgomery, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Arcadia, California, United States
GSK Investigational Site
Duarte, California, United States
GSK Investigational Site
Glendale, California, United States
GSK Investigational Site
Laguna Hills, California, United States
GSK Investigational Site
Loma Linda, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Stanford, California, United States
GSK Investigational Site
Naples, Florida, United States
GSK Investigational Site
Pensacola, Florida, United States
GSK Investigational Site
Alpharetta, Georgia, United States
GSK Investigational Site
Hutchinson, Kansas, United States
GSK Investigational Site
Kansas City, Kansas, United States
GSK Investigational Site
Baton Rouge, Louisiana, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Jackson, Mississippi, United States
GSK Investigational Site
New Brunswick, New Jersey, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Winchester, Virginia, United States
GSK Investigational Site
Wenatchee, Washington, United States
GSK Investigational Site
Aalst, , Belgium
GSK Investigational Site
Braasschaat, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Ste-Foy, Quebec, Canada
GSK Investigational Site
Marburg, Hesse, Germany
GSK Investigational Site
Aachen, North Rhine-Westphalia, Germany
GSK Investigational Site
Koblenz, Rhineland-Palatinate, Germany
GSK Investigational Site
Győr, , Hungary
GSK Investigational Site
Kistarcsa, , Hungary
GSK Investigational Site
Miskolc, , Hungary
GSK Investigational Site
Székesfehérvár, , Hungary
GSK Investigational Site
Cadiz, , Spain
GSK Investigational Site
Cartagena, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Singla NK, Singla SK, Chung F, Kutsogiannis DJ, Blackburn L, Lane SR, Levin J, Johnson B, Pergolizzi JV Jr. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology. 2010 Jul;113(1):74-82. doi: 10.1097/ALN.0b013e3181d7b13a.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKT102260
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.